RT Journal Article
T1 Magnetic Nanoparticles as MRI Contrast Agents
A1 Avasthi, Ashish
A1 Caro, Carlos
A1 Pozo-Torres, Esther
A1 Pernia Leal, Manuel
A1 García-Martín, María Luisa
K1 Magnetic nanoparticles
K1 Iron oxide nanoparticles
K1 Magnetic resonance imaging
K1 Cancer
K1 Diagnosis
K1 Nanopartículas magnéticas de óxido de hierro
K1 Imagen por resonancia magnética
K1 Neoplasias
K1 Diagnóstico
AB Iron oxide nanoparticles (IONPs) have emerged as a promising alternative to conventional contrast agents (CAs) for magnetic resonance imaging (MRI). They have been extensively investigated as CAs due to their high biocompatibility and excellent magnetic properties. Furthermore, the ease of functionalization of their surfaces with different types of ligands (antibodies, peptides, sugars, etc.) opens up the possibility of carrying out molecular MRI. Thus, IONPs functionalized with epithelial growth factor receptor antibodies, short peptides, like RGD, or aptamers, among others, have been proposed for the diagnosis of various types of cancer, including breast, stomach, colon, kidney, liver or brain cancer. In addition to cancer diagnosis, different types of IONPs have been developed for other applications, such as the detection of brain inflammation or the early diagnosis of thrombosis. This review addresses key aspects in the development of IONPs for MRI applications, namely, synthesis of the inorganic core, functionalization processes to make IONPs biocompatible and also to target them to specific tissues or cells, and finally in vivo studies in animal models, with special emphasis on tumor models.
PB SpringerNature
SN 2365-0869
YR 2020
FD 2020-05-07
LK http://hdl.handle.net/10668/3377
UL http://hdl.handle.net/10668/3377
LA en
NO Avasthi A, Caro C, Pozo-Torres E, Leal MP, García-Martín ML. Magnetic Nanoparticles as MRI Contrast Agents. Top Curr Chem (Cham). 2020 May 7;378(3):40. Erratum in: Top Curr Chem (Cham). 2021 Jun 14;379(4):30.
DS RISalud
RD Apr 4, 2025